MX2020009763A - Derivados de dihidrocromeno. - Google Patents
Derivados de dihidrocromeno.Info
- Publication number
- MX2020009763A MX2020009763A MX2020009763A MX2020009763A MX2020009763A MX 2020009763 A MX2020009763 A MX 2020009763A MX 2020009763 A MX2020009763 A MX 2020009763A MX 2020009763 A MX2020009763 A MX 2020009763A MX 2020009763 A MX2020009763 A MX 2020009763A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- hydrogen atoms
- sub
- formula
- dihydrochromene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018052971 | 2018-03-20 | ||
| PCT/JP2019/011439 WO2019181939A1 (ja) | 2018-03-20 | 2019-03-19 | ジヒドロクロメン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009763A true MX2020009763A (es) | 2020-10-08 |
Family
ID=67986459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009763A MX2020009763A (es) | 2018-03-20 | 2019-03-19 | Derivados de dihidrocromeno. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10807993B2 (https=) |
| EP (1) | EP3770162B1 (https=) |
| JP (4) | JP6733072B2 (https=) |
| KR (1) | KR102799186B1 (https=) |
| CN (1) | CN111886237B (https=) |
| AU (1) | AU2019239481B2 (https=) |
| CA (1) | CA3092255A1 (https=) |
| CY (1) | CY1126034T1 (https=) |
| DK (1) | DK3770162T3 (https=) |
| EA (1) | EA202092206A1 (https=) |
| ES (1) | ES2941771T3 (https=) |
| FI (1) | FI3770162T3 (https=) |
| HU (1) | HUE062256T2 (https=) |
| MX (1) | MX2020009763A (https=) |
| MY (1) | MY202583A (https=) |
| PH (1) | PH12020551497A1 (https=) |
| PL (1) | PL3770162T3 (https=) |
| PT (1) | PT3770162T (https=) |
| SG (1) | SG11202007979UA (https=) |
| TW (1) | TWI899051B (https=) |
| WO (1) | WO2019181939A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3770162T3 (pl) * | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2025100519A1 (ja) * | 2023-11-09 | 2025-05-15 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含むがんの治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| US20080255149A1 (en) * | 2005-09-27 | 2008-10-16 | Novartis Ag | Carboxyamine Compounds and Methods of Use Thereof |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| RU2018101897A (ru) * | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| CA2990583A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| TW201821105A (zh) * | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用ｈｄａｃ１１抑制劑之方法 |
| PL3770162T3 (pl) | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| JP2020019752A (ja) | 2018-08-03 | 2020-02-06 | 大日本住友製薬株式会社 | クロマン誘導体 |
-
2019
- 2019-03-19 PL PL19770755.7T patent/PL3770162T3/pl unknown
- 2019-03-19 TW TW108109362A patent/TWI899051B/zh active
- 2019-03-19 AU AU2019239481A patent/AU2019239481B2/en active Active
- 2019-03-19 PT PT197707557T patent/PT3770162T/pt unknown
- 2019-03-19 MX MX2020009763A patent/MX2020009763A/es unknown
- 2019-03-19 SG SG11202007979UA patent/SG11202007979UA/en unknown
- 2019-03-19 MY MYPI2020004784A patent/MY202583A/en unknown
- 2019-03-19 WO PCT/JP2019/011439 patent/WO2019181939A1/ja not_active Ceased
- 2019-03-19 HU HUE19770755A patent/HUE062256T2/hu unknown
- 2019-03-19 FI FIEP19770755.7T patent/FI3770162T3/fi active
- 2019-03-19 EP EP19770755.7A patent/EP3770162B1/en active Active
- 2019-03-19 CN CN201980020335.0A patent/CN111886237B/zh active Active
- 2019-03-19 EA EA202092206A patent/EA202092206A1/ru unknown
- 2019-03-19 DK DK19770755.7T patent/DK3770162T3/da active
- 2019-03-19 KR KR1020207029401A patent/KR102799186B1/ko active Active
- 2019-03-19 ES ES19770755T patent/ES2941771T3/es active Active
- 2019-03-19 CA CA3092255A patent/CA3092255A1/en active Pending
- 2019-03-19 JP JP2020507833A patent/JP6733072B2/ja active Active
-
2020
- 2020-03-03 US US16/808,246 patent/US10807993B2/en active Active
- 2020-07-08 JP JP2020117566A patent/JP7247144B2/ja active Active
- 2020-07-31 US US16/944,482 patent/US11639357B2/en active Active
- 2020-09-18 PH PH12020551497A patent/PH12020551497A1/en unknown
-
2023
- 2023-03-15 JP JP2023040667A patent/JP7508620B2/ja active Active
- 2023-03-21 US US18/187,124 patent/US12398149B2/en active Active
- 2023-05-26 CY CY20231100250T patent/CY1126034T1/el unknown
-
2024
- 2024-06-19 JP JP2024098472A patent/JP2024123117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119882T1 (el) | Παραγωγο πυριμιδινης ως αναστολεας ρι3κ και χρηση αυτου | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| ZA202108263B (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| MX2020009763A (es) | Derivados de dihidrocromeno. | |
| MX2022003740A (es) | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. | |
| MX2010001745A (es) | Imidazoles fusionados para el tratamiento del cancer. | |
| CY1119844T1 (el) | 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων | |
| MX2013002558A (es) | Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk). | |
| TR201011157T1 (tr) | Diglisidik eter türevi terapotikleri ve bunların kullanılma yöntemleri. | |
| CR11021A (es) | Derivados de quinolina como fungicidas | |
| JOP20210083B1 (ar) | مترافقات عقار جسم مضاد تشتمل على مشتقات إكتيناسكيدين | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
| ATE514703T1 (de) | Hydrolyseresistente organomodifizierte disiloxantenside | |
| CY1113812T1 (el) | Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης | |
| CN105358522A8 (en) | Ester derivatives of androgen receptor modulators and methods for their use | |
| WO2011141716A3 (en) | Modulators of chk-1 activity | |
| EP4464334A3 (en) | Use of compounds for treating hk2-expressing cancers | |
| CY1113486T1 (el) | Συντηγμενες δικυκλικες πυριμιδινες | |
| MX378221B (es) | Conjugados de pirrolobenzodiazepina | |
| AU2015217450A8 (en) | Pyrazolone compounds and uses thereof | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| EA201690230A1 (ru) | Соединения триазолона и их применения | |
| EP4316504A3 (en) | Compounds |